Kyverna Therapeutics reported total assets of $219.82M and total liabilities of $54.27M for the quarter ended Jun 2026, down 3.0% year over year. This balance sheet covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Depreciation | 2.49M | 2.73M | 3.02M | 3.35M | 3.67M | 3.93M | 4.21M | 3.58M | 3.75M | 3.87M | 3.29M | |||
| Receivables - AccuredAcc. Int. Receivables | 0.40M | 0.10M | 0.30M | 0.60M | 1.20M | 1.70M | ||||||||
| Assets | ||||||||||||||
| Current Assets | ||||||||||||||
| Cash & EquivalentsCash & Equiv. | 39.79M | 53.43M | 22.97M | 34.65M | 224.29M | 131.62M | 104.66M | 96.62M | 56.87M | 53.44M | 34.16M | 124.09M | 32.19M | 31.81M |
| Prepaid Assets | 3.12M | 5.69M | 2.59M | 3.79M | 4.62M | 5.00M | 2.65M | 3.79M | 3.70M | 5.28M | 7.12M | |||
| Current Assets | 60.66M | 375.49M | 348.82M | 325.37M | 290.60M | 247.65M | 214.33M | 174.93M | 282.95M | 241.73M | 206.54M | |||
| Non-Current Assets | ||||||||||||||
| Property, Plant & Equipment (Net) | 2.33M | 2.71M | 3.37M | 3.15M | 3.35M | 2.44M | 2.16M | 1.79M | 1.55M | 1.34M | 1.33M | |||
| Other Non-Current Assets | 3.36M | 1.17M | 1.21M | 1.88M | 2.84M | 3.64M | 4.05M | 5.36M | 4.90M | 5.01M | 3.44M | |||
| Non-Current Assets | 14.53M | 14.50M | 14.29M | 13.82M | 14.04M | 13.00M | 12.18M | 12.23M | 10.87M | 15.30M | 13.28M | |||
| Assets | 75.19M | 389.98M | 363.12M | 339.20M | 304.64M | 260.65M | 226.51M | 187.16M | 293.83M | 257.02M | 219.82M | |||
| Liabilities | ||||||||||||||
| Current Liabilities | ||||||||||||||
| Accounts Payables | 4.36M | 7.45M | 4.86M | 9.93M | 4.62M | 8.47M | 9.92M | 3.02M | 5.31M | 11.60M | 2.93M | |||
| Payables | 4.36M | 7.45M | 4.86M | 9.93M | 4.62M | 8.47M | 9.92M | 3.02M | 5.31M | 11.60M | 2.93M | |||
| Accumulated Expenses | 2.81M | 1.36M | 2.72M | 4.44M | 4.88M | 3.08M | 4.97M | 6.96M | 9.99M | 3.11M | 5.48M | |||
| Other Accumulated Expenses | 1.79M | 2.90M | 1.76M | 1.23M | 2.04M | 2.17M | 3.02M | 4.00M | ||||||
| Current Leases | 1.96M | 2.74M | 2.87M | 3.00M | 3.16M | 3.08M | 3.28M | 3.50M | 3.66M | 1.76M | 1.40M | |||
| Total Current Liabilities | 19.86M | 21.86M | 23.48M | 30.98M | 33.76M | 33.29M | 39.79M | 33.87M | 36.49M | 29.67M | 22.80M | |||
| Non-Current Liabilities | ||||||||||||||
| Capital Leases | 0.92M | 0.67M | 0.41M | 0.24M | 0.14M | 0.07M | 0.03M | 0.01M | ||||||
| Non-Current Debt | 24.74M | 24.81M | 24.88M | |||||||||||
| Preferred Stock Liabilities | 120.67M | 145.73M | 180.57M | 180.57M | ||||||||||
| Operating Leases | 5.24M | 6.46M | 5.72M | 4.97M | 4.16M | 3.28M | 2.32M | 1.33M | 0.32M | 6.96M | 6.59M | |||
| Other Non-Current Liabilities | 0.30M | |||||||||||||
| Total Non-Current Liabilities | 36.19M | |||||||||||||
| Total Liabilities | 84.61M | 97.19M | 111.81M | 26.02M | 28.99M | 29.61M | 36.49M | 38.06M | 36.65M | 42.13M | 35.21M | 61.55M | 61.44M | 54.27M |
| Shareholder's Equity | ||||||||||||||
| Total Debt | 24.74M | 24.81M | 24.88M | |||||||||||
| Common Equity | -84.61M | -97.19M | -111.81M | -13.14M | 360.99M | 333.51M | 302.71M | 266.59M | 224.01M | 184.38M | 151.95M | 232.28M | 195.58M | 165.55M |
| Liabilities and Shareholders Equity | 75.19M | 389.98M | 363.12M | 339.20M | 304.64M | 260.65M | 226.51M | 187.16M | 293.83M | 257.02M | 219.82M | |||
| Retained Earnings | -136.04M | -162.74M | -191.54M | -226.03M | -263.52M | -308.20M | -350.24M | -387.02M | -424.83M | -464.60M | -502.90M | |||
| Treasury Shares | 82.50M | 95.92M | 114.56M | 114.56M |